Annovis Bio, Inc.ANVSNYSE
LOADING
|||
Switch Symbol:
R&D Expense Growth Recovery in Progress
Trending higher, below historical average.
Left:
||||
Year-over-year research & development expense growth
Latest
21.88%
↓ 98% below average
Average (30q)
1259.48%
Historical baseline
Range
High:37762.99%
Low:-91.28%
Volatility
3005.5%
High variability
| Period | Value |
|---|---|
| Q3 2025 | 21.88% |
| Q2 2025 | 3.00% |
| Q1 2025 | 0.26% |
| Q4 2024 | 85.85% |
| Q3 2024 | -53.51% |
| Q2 2024 | -11.20% |
| Q1 2024 | -26.84% |
| Q4 2023 | -35.65% |
| Q3 2023 | 67.48% |
| Q2 2023 | 6.11% |
| Q1 2023 | 25.41% |
| Q4 2022 | 50.56% |
| Q3 2022 | 2.22% |
| Q2 2022 | 87.66% |
| Q1 2022 | -25.47% |
| Q4 2021 | 108.87% |
| Q3 2021 | -24.32% |
| Q2 2021 | -23.65% |
| Q1 2021 | 69.21% |
| Q4 2020 | 96.44% |
| Q3 2020 | -16.06% |
| Q2 2020 | 1188.98% |
| Q1 2020 | -91.28% |
| Q4 2019 | 37762.99% |
| Q3 2019 | -66.67% |
| Q2 2019 | 0.32% |
| Q1 2019 | -54.69% |
| Q4 2018 | 0.14% |
| Q3 2018 | -51.27% |
| Q2 2018 | -52.89% |
| Q1 2018 | 0.00% |